Meyka Pro banner
Evolus, Inc.

Evolus, Inc. Fundamental Analysis (NASDAQ: EOLS)

EOLS●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$7.42
$0.61(8.96%)
U.S. Market opens in 12h 58m

Evolus, Inc. Fundamental Analysis (NASDAQ: EOLS)

Evolus, Inc. (NASDAQ: EOLS) shows moderate financial fundamentals with a PE ratio of -15.64, profit margin of -9.56%, and ROE of 1.03%. The company generates $0.3B in annual revenue with strong year-over-year growth of 11.61%.

Key Strengths

PEG Ratio-0.21

Areas of Concern

ROE1.03%
Operating Margin-5.69%
We analyze EOLS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 95.1/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
95.1/100

We analyze EOLS's fundamental strength across five key dimensions:

Efficiency Score

Weak

EOLS struggles to generate sufficient returns from assets.

ROA > 10%
-10.96%

Valuation Score

Excellent

EOLS trades at attractive valuation levels.

PE < 25
-15.64
PEG Ratio < 2
-0.21

Growth Score

Moderate

EOLS shows steady but slowing expansion.

Revenue Growth > 5%
11.61%
EPS Growth > 10%
1.23%

Financial Health Score

Excellent

EOLS maintains a strong and stable balance sheet.

Debt/Equity < 1
-4.38
Current Ratio > 1
1.42

Profitability Score

Weak

EOLS struggles to sustain strong margins.

ROE > 15%
103.19%
Net Margin ≥ 15%
-9.56%
Positive Free Cash Flow
No

Key Financial Metrics

Is EOLS Expensive or Cheap?

P/E Ratio

EOLS trades at -15.64 times earnings. This suggests potential undervaluation.

-15.64

PEG Ratio

When adjusting for growth, EOLS's PEG of -0.21 indicates potential undervaluation.

-0.21

Price to Book

The market values Evolus, Inc. at -12.79 times its book value. This may indicate undervaluation.

-12.79

EV/EBITDA

Enterprise value stands at -81.53 times EBITDA. This is generally considered low.

-81.53

How Well Does EOLS Make Money?

Net Profit Margin

For every $100 in sales, Evolus, Inc. keeps $-9.56 as profit after all expenses.

-9.56%

Operating Margin

Core operations generate -5.69 in profit for every $100 in revenue, before interest and taxes.

-5.69%

ROE

Management delivers $1.03 in profit for every $100 of shareholder equity.

1.03%

ROA

Evolus, Inc. generates $-10.96 in profit for every $100 in assets, demonstrating efficient asset deployment.

-10.96%

Following the Money - Real Cash Generation

Operating Cash Flow

Evolus, Inc. generates limited operating cash flow of $-2.65M, signaling weaker underlying cash strength.

$-2.65M

Free Cash Flow

Evolus, Inc. generates weak or negative free cash flow of $-7.32M, restricting financial flexibility.

$-7.32M

FCF Per Share

Each share generates $-0.11 in free cash annually.

$-0.11

FCF Yield

EOLS converts -1.50% of its market value into free cash.

-1.50%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-15.64

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.21

vs 25 benchmark

P/B Ratio

Price to book value ratio

-12.79

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.49

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-4.38

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.42

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.03

vs 25 benchmark

ROA

Return on assets percentage

-0.11

vs 25 benchmark

ROCE

Return on capital employed

-0.13

vs 25 benchmark

How EOLS Stacks Against Its Sector Peers

MetricEOLS ValueSector AveragePerformance
P/E Ratio-15.6431.66 Better (Cheaper)
ROE103.19%501.00% Weak
Net Margin-9.56%-3647.00% (disorted) Weak
Debt/Equity-4.38-0.30 (disorted) Distorted
Current Ratio1.425.78 Neutral
ROA-10.96%-262.00% (disorted) Weak

EOLS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evolus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

175.06%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

83.42%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

61.78%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ